Elsevier

Vaccine

Volume 15, Issue 10, July 1997, Pages 1157-1161
Vaccine

Paper
The effect of age and weight on the response to formalin inactivated, alum-adjuvanted hepatitis A vaccine in healthy adults

https://doi.org/10.1016/S0264-410X(96)00310-6Get rights and content

Abstract

Formalin-inactivated, alum-adsorbed, hepatitis A vaccine was evaluated in 100 healthy adults who were stratified at enrollment into two age groups: 18–39 years: n=50; 40–65 years: n=50. All individuals received vaccine at 25 U of viral antigen. After stratification, both groups were randomized to receive either vaccination at 0 and 24 weeks or vaccination at 0, 2 and 24 weeks. Subjects were bled for serology at 0, 2, 4, 24, 28 weeks and 1 year. The seroconversion rate and geometric mean titer (GMT=mIU ml−1) after one dose of vaccine was lower for older subjects [second week: <40 years: 1525 (60%) (GMT: 12.9), >40 years: 522 (23%) (GMT: 6.1); fourth week: <40 years: 2022 (91%) (GMT: 29.0), >40 years: 1623 (70%) (GMT: 14.3)]. After a second dose at 2 weeks the seroresponse improved so that there were no longer differences between age groups [24 weeks: <40: 2122 (95%) (GMT: 123.9), >40: 2223 (96%) (GMT: 106.1)]. A third dose at 24 weeks resulted in a 20–40-fold increase in GMT in both age groups. As a separate evaluation height, weight, skin fold thickness, and body mass index (BMI) were assessed by logistic regression for their ability to predict serologic response. Serologic response was significantly associated with lower weight (P=0.032) and BMI (P=0.024) but not with height or skin fold thickness. Hepatitis A vaccine was well tolerated, with no serious adverse experiences. Adults older than 40 years appear to respond less well than younger adults to a single dose of 25 U of hepatitis A vaccine but equally well after two doses of vaccine. The slower antibody response to hepatitis A vaccine in overweight individuals was not attributable to skin adipose tissue.

References (17)

There are more references available in the full text version of this article.

Cited by (72)

  • Use of hepatitis A vaccine for post-exposure prophylaxis in individuals over 40 years of age: A systematic review of published studies and recommendations for vaccine use

    2018, Vaccine
    Citation Excerpt :

    At 30 days post-vaccination, however, 97% of individuals in both groups had seroconverted. Reuman et al., which used a lower dose of VAQTA than currently recommended for adults in the U.S., also found somewhat lower responses in the older age group two weeks after vaccination [17]. In the <40 year age group, 56% of individuals seroconverted (n = 50; P = 0.017) at two weeks post-vaccination compared with only 31% in the ≥40 year age group (n = 45).

  • Hepatitis A Vaccines

    2017, Plotkin's Vaccines
  • Rubella seronegativity in antenatal screening - Is it influenced by the introduction of universal childhood rubella immunization?

    2015, Vaccine
    Citation Excerpt :

    The immune response to childhood rubella vaccination can be influenced by age at vaccination, as rubella seropositivity was highest in children aged 6–11 years (96.2%), followed by children aged 12–19 years (93.7%), and lowest in adult women (88.9–91.5) in the US where vaccination coverage is >90% [32]. Aging impairs T-cell function [33–35], and together with factors like overweight, gender, and vaccine regimen, all influence the individual's response to vaccines such as hepatitis A vaccine [36] and combined hepatitis A/B vaccine [37]. Therefore advanced age, high BMI, and vaccine regimen, have to be included in our analysis.

  • The weight of obesity on the human immune response to vaccination

    2015, Vaccine
    Citation Excerpt :

    Elevated BMI was identified as the most significant factor correlated with a significant decline (p < 0.05) in anti-HAV titers and the third most significant factor for poor vaccine-induced anti-HBs titers. Another study [44] observed a slower antibody response to HAV vaccination in overweight individuals, despite an increase in antibody response after a second booster dose. When anti-HAV titers were measured four weeks post-vaccination, both weight (p = 0.019) and BMI (p = 0.016) were significant predictors of non-protective (anti-HAV titers < 10 mIU/mL) seroresponse, with the odds of being a responder increasing as weight and BMI decreased.

  • An outbreak of hepatitis A virus associated with a multi-national inner-city nursery in Glasgow, Scotland

    2015, Journal of Clinical Virology
    Citation Excerpt :

    Of interest, case 5 developed HAV one week after HAV vaccination. This serves as a reminder that post-exposure prophylaxis with HAV vaccine is only 79% effective when administered 1–14 days post-exposure, and may be less efficacious in patients over 40 years old [10–12]. In this instance, she was likely to have been already incubating HAV when vaccination was given.

View all citing articles on Scopus
View full text